SynAct Pharma AB
STO:SYNACT
Income Statement
Earnings Waterfall
SynAct Pharma AB
Income Statement
SynAct Pharma AB
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(77)
|
(85)
|
(96)
|
(101)
|
(106)
|
(142)
|
(159)
|
(164)
|
(150)
|
(192)
|
(168)
|
(160)
|
(90)
|
(92)
|
(104)
|
(115)
|
|
| Selling, General & Administrative |
(16)
|
(22)
|
(31)
|
(33)
|
(35)
|
(42)
|
(44)
|
(48)
|
(44)
|
(48)
|
(45)
|
(40)
|
(40)
|
(29)
|
(24)
|
(27)
|
|
| Research & Development |
(60)
|
(63)
|
(64)
|
(69)
|
(70)
|
(100)
|
(115)
|
(116)
|
(105)
|
(69)
|
(48)
|
(46)
|
(49)
|
(63)
|
(79)
|
(88)
|
|
| Depreciation & Amortization |
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(75)
|
(75)
|
(75)
|
0
|
(0)
|
0
|
1
|
|
| Operating Income |
(77)
N/A
|
(85)
-11%
|
(96)
-13%
|
(101)
-6%
|
(106)
-4%
|
(142)
-34%
|
(159)
-12%
|
(164)
-3%
|
(150)
+9%
|
(192)
-28%
|
(168)
+13%
|
(160)
+4%
|
(90)
+44%
|
(92)
-3%
|
(104)
-12%
|
(115)
-11%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(3)
|
(2)
|
(2)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(75)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(77)
N/A
|
(85)
-11%
|
(97)
-14%
|
(103)
-6%
|
(107)
-4%
|
(143)
-33%
|
(159)
-11%
|
(164)
-3%
|
(224)
-37%
|
(192)
+14%
|
(168)
+12%
|
(161)
+4%
|
(91)
+44%
|
(95)
-5%
|
(105)
-11%
|
(116)
-10%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
8
|
7
|
8
|
8
|
8
|
14
|
11
|
9
|
8
|
1
|
2
|
6
|
8
|
13
|
14
|
10
|
|
| Income from Continuing Operations |
(69)
|
(78)
|
(89)
|
(95)
|
(99)
|
(129)
|
(148)
|
(156)
|
(216)
|
(191)
|
(166)
|
(155)
|
(82)
|
(82)
|
(91)
|
(106)
|
|
| Net Income (Common) |
(69)
N/A
|
(78)
-12%
|
(89)
-15%
|
(95)
-6%
|
(99)
-4%
|
(129)
-30%
|
(148)
-15%
|
(156)
-5%
|
(216)
-39%
|
(191)
+12%
|
(166)
+13%
|
(155)
+7%
|
(82)
+47%
|
(82)
+0%
|
(91)
-11%
|
(106)
-17%
|
|
| EPS (Diluted) |
-2.64
N/A
|
-2.97
-13%
|
-3.26
-10%
|
-3.34
-2%
|
-3.56
-7%
|
-4.11
-15%
|
-4.64
-13%
|
-4.89
-5%
|
-6.58
-35%
|
-5.31
+19%
|
-4.17
+21%
|
-3.7
+11%
|
-2.08
+44%
|
-1.69
+19%
|
-1.85
-9%
|
-2
-8%
|
|